

Iprivask™ 15 mg  
[Desirudin for Injection]

R<sub>x</sub> only

#### **SPINAL/EPIDURAL HEMATOMAS**

When neuraxial anesthesia (epidural/spinal anesthesia) or spinal puncture is employed, patients anticoagulated or scheduled to be anticoagulated with selective inhibitors of thrombin such as Iprivask may be at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.

The risk of these events may be increased by the use of indwelling spinal catheters for administration of analgesia or by the concomitant use of drugs affecting hemostasis such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants. Likewise with such agents, the risk appears to be increased by traumatic or repeated epidural or spinal puncture.

Patients should be frequently monitored for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

The physician should consider the potential benefit versus risk before neuraxial intervention, in patients anticoagulated or to be anticoagulated for thromboprophylaxis (see also **WARNINGS**).


#### **DESCRIPTION**

Iprivask [Desirudin for Injection] is a specific inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, *Hirudo medicinalis*. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C<sub>287</sub>H<sub>440</sub>N<sub>80</sub>O<sub>110</sub>S<sub>6</sub> with a molecular weight of 6963.52. Desirudin, which is expressed in yeast (*Saccharomyces cerevisiae*, strain TR 1456) by recombinant DNA technology differs from the natural hirudin by lack of a sulfate group on Tyr-63. The biological activity of desirudin is determined through a chromogenic assay which measures the ability of desirudin to inhibit the hydrolysis of a chromogenic peptidic substrate by thrombin in comparison to a desirudin standard. One vial of desirudin contains 15.75 mg desirudin corresponding to approximately 315,000 antithrombin units (ATU) or 20,000 ATU per milligram of desirudin with reference to the WHO International Standard (prepared 1991) for alphanthrombin.

Iprivask 15 mg is supplied as a sterile, white, freeze dried powder for injection. Each **vial** contains 15.75 mg desirudin and the following inactive ingredients: 1.31 mg anhydrous magnesium chloride USP, sodium hydroxide for injection USP. Each **ampule** of diluent for Iprivask contains 0.6 mL sterile Mannitol USP (3%) in Water for Injection and is preservative free. See DOSAGE AND ADMINISTRATION section for reconstitution instructions. Iprivask 15 mg is administered by subcutaneous (SC) injection, preferably at an abdominal or thigh site.

To prepare the reconstituted aqueous solution, 0.5 mL of the mannitol diluent is added under aseptic conditions to the vial containing the sterile powder. Shaking gently rapidly disperses the drug. The reconstituted solution has a pH of 7.4.

## STRUCTURAL FORMULA




## CLINICAL PHARMACOLOGY

**Mechanism of Action:** Desirudin is a selective inhibitor of free circulating and clot-bound thrombin. The anticoagulant properties of desirudin are demonstrated by its ability to prolong the clotting time of human plasma. One molecule of desirudin binds to one molecule of thrombin and thereby blocks the thrombogenic activity of thrombin. As a result, all thrombin-dependent coagulation assays are affected. Activated partial thromboplastin time (aPTT) is a measure of the anticoagulant activity of desirudin and increases in a dose-dependent fashion. The pharmacodynamic effect of desirudin on proteolytic activity of thrombin was assessed as an increase in aPTT. A mean peak aPTT prolongation of about 1.38 times baseline value (range 0.58 to 3.41) was observed following subcutaneous b.i.d. injections of 15 mg desirudin. Thrombin time (TT) frequently exceeds 200 seconds even at low plasma concentrations of desirudin, which renders this test unsuitable for routine monitoring of Iprivask therapy. At therapeutic serum concentrations, desirudin has no effect on other enzymes of the hemostatic system such as factors IXa, Xa, kallikrein, plasmin, tissue plasminogen activator, or activated protein C. In addition, it does not display any effect on other serine proteases, such as the digestive enzymes trypsin, chymotrypsin, or on complement activation by the classical or alternative pathways.

### Pharmacokinetic Properties

Pharmacokinetic parameters were calculated based on plasma concentration data obtained by a non-specific ELISA method that does not discriminate between native desirudin and its metabolites. It is not known if the metabolites are pharmacologically active.

**Absorption:** The absorption of desirudin is complete when subcutaneously administered at doses of 0.3 mg/kg or 0.5 mg/kg. Following subcutaneous administration of single doses of 0.1 to 0.75 mg/kg, plasma concentrations of desirudin increased to a maximum level ( $C_{max}$ ) between 1 and 3 hours. Both  $C_{max}$  and area-under-the-curve (AUC) values are dose proportional.



**Distribution:** The pharmacokinetic properties of desirudin following intravenous (IV) administration are well described by a two- or three- compartment disposition model. Desirudin is distributed in the extracellular space with a volume of distribution at steady state of 0.25 L/kg, independent of the dose. Desirudin binds specifically and directly to thrombin, forming an extremely tight, non-covalent complex with an inhibition constant of approximately  $2.6 \times 10^{-13}$  M. Thus, free or protein bound desirudin immediately binds circulating thrombin. The pharmacological effect of desirudin is not modified when co-administered with highly protein bound drugs (>99%).

**Metabolism:** Human and animal data suggest that desirudin is primarily eliminated and metabolized by the kidney. The total urinary excretion of unchanged desirudin amounts to 40 to 50% of the administered dose. Metabolites lacking one or two C-terminal amino acids constitute a minor proportion of the material recovered from urine (< 7%). There is no evidence for the presence of other metabolites. This indicates that desirudin is metabolized by stepwise degradation from the C-terminus probably catalyzed by carboxypeptidase(s) such as carboxypeptidase A, originating from the pancreas. Total clearance of desirudin is approximately 1.5 to 2.7 mL/min/kg following either subcutaneous or IV administration and is independent of dose. This clearance value is close to the glomerular filtration rate.

**Elimination:** The elimination of desirudin from plasma is rapid after IV administration, with approximately 90% of the dose disappearing from the plasma within 2 hours of the injection. Plasma concentrations of desirudin then decline with a mean terminal elimination half-life of 2 to 3 hours. After subcutaneous administration, the mean terminal elimination half-life is also approximately 2 hours.

### Special Populations:

**Renal Insufficiency:** In a pharmacokinetic study of renally impaired subjects, subjects with mild [creatinine clearance (CC) between 61 and 90 mL/min/1.73 m<sup>2</sup> body surface area], moderate (CC between 31 and 60 mL/min/1.73 m<sup>2</sup> body surface area), and severe (CC below 31 mL/min/1.73 m<sup>2</sup> body surface area) renal insufficiency, were administered a single IV dose of 0.5, 0.25, or 0.125 mg/kg desirudin, respectively. This resulted in mean dose-normalized AUC<sub>effect</sub> (AUC<sub>0-60th</sub> for aPTT prolongation) increases of approximately 3-, and 9-fold for the moderate and severe renally impaired subjects, respectively, compared with healthy individuals. In subjects with mild renal impairment,

there was no increase in  $AUC_{\text{effect}}$  compared with healthy individuals. In subjects with severe renal insufficiency, terminal elimination half-lives were prolonged up to 12 hours compared with 2 to 4 hours in normal volunteers or subjects with mild to moderate renal insufficiency (see **WARNINGS**). Dose adjustments are recommended in certain circumstances in relation to the degree of impairment or degree of aPTT abnormality (see **WARNINGS: Renal Insufficiency**, **PRECAUTIONS: Laboratory Tests**, and **DOSAGE AND ADMINISTRATION: Monitoring and Adjusting Therapy; Use in Renal Insufficiency**).

*Hepatic Insufficiency:* No pharmacokinetic studies have been conducted to investigate the effects of Iprivask in hepatic insufficiency (see **PRECAUTIONS, Hepatic Insufficiency/Liver Injury** and **DOSAGE and ADMINISTRATION**).

*Age/Gender:* The mean plasma clearance of desirudin in patients  $\geq 65$  years of age ( $n=12$ ; 110 mL/min) is approximately 28% lower than in patients  $<65$  years of age ( $n=8$ ; 153 mL/min). Population pharmacokinetics conducted in 301 patients undergoing elective total hip replacement indicate that age or gender do not affect the systemic clearance of desirudin when renal creatinine clearance is considered. This drug is substantially excreted by the kidney, and the risk of adverse events due to it may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Dosage adjustment in the case of moderate and severe renal impairment is necessary. (See **CLINICAL PHARMACOLOGY, Special Populations, Renal Insufficiency, DOSAGE and ADMINISTRATION, Use in Renal Insufficiency**).

## CLINICAL TRIALS

Iprivask was evaluated in two controlled, randomized, multicenter, clinical efficacy trials and a controlled, double-blind, dose-finding study. In the efficacy studies, Iprivask was compared to subcutaneously administered unfractionated heparin or enoxaparin sodium for the reduction of the risk of venous thromboembolic events (VTE) in patients undergoing total hip replacement surgery. In all studies Iprivask was initiated prior to surgery and continued for 8 to 12 days postoperatively (median duration 10 days). Patients who received Iprivask had a lower incidence of VTE. The efficacy studies are described below.

In the first study, Iprivask 15 mg subcutaneously administered every 12 hours was compared to unfractionated heparin 5000 IU subcutaneously administered every 8 hours. A total of 445 patients were randomized in the study, 436 patients were treated, and 85 of the treated patients were excluded from efficacy analysis, mainly because of no phlebography or inadequate reading of phlebography. Patients ranged in age from 34 to 89 years (mean age 68.4 years) with 41.8% men and 58.2% women. All enrolled patients were Caucasian. Iprivask significantly reduced the number of total VTE compared to unfractionated heparin: Evaluable population: Iprivask, 13/174 (7.5%) vs. heparin, 41/177 (23.2%);  $p$  value  $<0.001$ ; Intent-to-Treat population: Iprivask 13/225 (5.8%) vs. heparin 42/220 (19.1%);  $p$  value  $<0.0001$ .]. Significantly fewer patients in the group treated with Iprivask experienced proximal DVT than those patients treated with heparin: Evaluable population: Iprivask 6/174 (3.4%) vs. heparin 29/177 (16.4%);  $p$  value  $<0.001$ ; Intent-to-Treat population: Iprivask 6/225 (2.7%) vs. heparin 30/220 (13.6%);  $p$  value  $<0.0001$ .

In a second study, Iprivask 15 mg subcutaneously administered every 12 hours was compared to enoxaparin sodium 40 mg subcutaneously administered every 24 hours. A total of 2079 patients were randomized in the study, 2049 patients were treated, and 508 of the treated patients were excluded from efficacy analysis mainly because of no phlebography or inadequate reading of phlebography. Patients ranged in age from 18 to 90 years (mean age 68.5 years) with 41.7% men and 58.5% women. All enrolled patients were Caucasian. In the both the evaluable patient population and the intent-to-treat population, patients who received Iprivask had a lower incidence of major VTE, total VTE, and proximal DVT than did patients who received enoxaparin (see table below).

Efficacy of Iprivask in Hip Replacement Surgery Patients			
	Dosing Regimen		
	Iprivask <sup>a</sup> 15 mg q12h SC	Enoxaparin <sup>a</sup> 40 mg qd	
Evaluable Hip Replacement Surgery Patients	n=773	n=768	
	n (%)	n (%)	p Value
Treatment failures			
Major VTE <sup>b,c</sup>	39 (4.9) <sup>d</sup>	61 (7.9)	p<0.02
Total VTE <sup>e</sup>	145 (18.8)	197 (25.7)	p<0.001
Proximal DVT	36 (4.5)	59 (7.7)	p=0.012
Intent-to-Treat Hip Replacement Surgery Patients	n=1043	n=1036	
	n (%)	n (%)	p Value
Treatment Failures			
Major VTE <sup>b</sup>	39 (3.7) <sup>f</sup>	61 (5.9)	p=0.024
Total VTE <sup>e</sup>	145 (13.9)	199 (19.2)	p=0.001
Proximal DVT	36 (3.5)	59 (5.7)	p=0.012

<sup>a</sup>Treatment was initiated no more than 30 minutes preoperatively, but *after* induction of regional block anesthesia, if used.

<sup>b</sup>Major VTE included proximal DVT, PE, or death.

<sup>c</sup>Total number of patients in this evaluation: Iprivask 802; Enoxaparin 785.

<sup>d</sup>Odds ratio 0.61 with 95% Confidence Interval of: 0.40; 0.92

<sup>e</sup>Total VTE = Venous thromboembolic events which included DVT (including proximal events), PE, or death considered to be thromboembolic in origin.

<sup>f</sup>Odds ratio 0.62 with 95% Confidence Interval of 0.41; 0.94

In a multicenter, double-blind, dose-finding study, Iprivask 10 mg, 15 mg, and 20 mg subcutaneously administered every 12 hours was compared to unfractionated heparin 5,000 IU administered every 8 hours SC in patients undergoing hip replacement surgery. A dose response was seen with regard to both effectiveness and bleeding complications. The 15-mg and 20-mg doses were superior to heparin and the 10-mg dose. In a smaller, open-labeled, dose-finding study of Iprivask 10 mg, 15 mg, 20 mg, and 40 mg subcutaneously administered every 12 hours in patients undergoing hip replacement surgery, the 40-mg dose was associated with unacceptable major bleeding.

## INDICATIONS AND USAGE

Iprivask is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing elective hip replacement surgery.

## CONTRAINDICATIONS

Iprivask is contraindicated in patients with known hypersensitivity to natural or recombinant hirudins, and in patients with active bleeding and/or irreversible coagulation disorders.

## WARNINGS

**Renal Insufficiency:** Iprivask must be used with caution in patients with renal impairment, particularly in those with moderate and severe renal impairment (creatinine clearance  $\leq 60$  mL/min/1.73 m<sup>2</sup> body surface area) (see **CLINICAL PHARMACOLOGY, Special Populations, Renal Insufficiency**). Dose reductions by factors of three and nine are recommended for patients with moderate and severe renal impairment respectively (see **DOSAGE AND ADMINISTRATION**). In addition, daily aPTT and serum creatinine monitoring are recommended for patients with moderate or severe renal impairment (see **PRECAUTIONS, Laboratory Tests**).

**Hemorrhagic Events:** Iprivask is not intended for intramuscular injection as local hematoma formation may result.

Iprivask, like other anticoagulants, should be used with caution in patients with increased risks of hemorrhage such as those with recent major surgery, organ biopsy or puncture of a non-compressible vessel within the last month; a history of hemorrhagic stroke, intracranial or intraocular bleeding including diabetic (hemorrhagic) retinopathy; recent ischemic stroke, severe uncontrolled hypertension, bacterial endocarditis, a known hemostatic disorder (congenital or acquired, e.g. hemophilia, liver disease) or a history of gastrointestinal or pulmonary bleeding within the past 3 months.

Bleeding can occur at any site during therapy with Iprivask. An unexplained fall in hematocrit or blood pressure should lead to a search for a bleeding site.

**Spinal/Epidural Anesthesia:** As with other anticoagulants, there is a risk of neuraxial hematoma formation with the concurrent use of desirudin and spinal/epidural anesthesia, which has the potential to result in long term or permanent paralysis. The risk may be greater with the use of post-operative indwelling catheters or the concomitant use of additional drugs affecting hemostasis such as NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), platelet inhibitors or other anticoagulants (see **Boxed WARNING** and **PRECAUTIONS, Drug Interactions**). The risk may also be increased by traumatic or repeated neuraxial puncture.

To reduce the potential risk of bleeding associated with the concurrent use of desirudin and epidural or spinal anesthesia/analgesia, the pharmacokinetic profile of the drug should be considered (see **CLINICAL PHARMACOLOGY, Pharmacokinetic properties**) when scheduling or using epidural or spinal anesthesia in proximity to desirudin administration. The physician should consider placement of the catheter prior to initiating desirudin and removal of the catheter when the anticoagulant effect of desirudin is low (see **DOSAGE and ADMINISTRATION**).

Should the physician decide to administer anticoagulation in the context of epidural/spinal anesthesia, extreme vigilance and frequent monitoring must be exercised to detect any signs and symptoms of neurological impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), bowel and/or bladder dysfunction. Patients should be instructed to inform their

physician immediately if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, urgent diagnosis and treatment including spinal cord decompression should be initiated.

The physician should consider the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis (see also **WARNINGS, Hemorrhage,** and **PRECAUTIONS, Drug Interactions**).

Iprivask cannot be used interchangeably with other hirudins as they differ in manufacturing process and specific biological activity (ATUs). Each of these medicines has its own instructions for use.

## **PRECAUTIONS**

**Antibodies/Re-exposure:** Antibodies have been reported in patients treated with hirudins. Potential for cross-sensitivity to hirudin products cannot be excluded. Irritative skin reactions were observed in 9/322 volunteers exposed to Iprivask by subcutaneous injection or IV bolus or infusion in single or multiple administrations of the drug. Allergic events were reported in <2% of patients who were administered desirudin in Phase III clinical trials. Allergic events were reported in 1% of patients receiving unfractionated heparin and 1% of patients receiving enoxaparin. Hirudin-specific IgE evaluations may not be indicative of sensitivity to Iprivask as this test was not always positive in the presence of symptoms. Very rarely, anti-hirudin antibodies have been detected upon re-exposure to desirudin. (See **ADVERSE REACTIONS, Non-hemorrhagic Events, Allergic Reactions**). Fatal anaphylactoid reactions have been reported during hirudin therapy.

**Hepatic Insufficiency/Liver Injury:** No information is available about the use of desirudin in patients with hepatic insufficiency/liver injury. Although Iprivask is not significantly metabolized by the liver, hepatic impairment or serious liver injury (*e.g.*, liver cirrhosis) may alter the anticoagulant effect of Iprivask due to coagulation defects secondary to reduced generation of vitamin K-dependent coagulation factors. Iprivask should be used with caution in these patients.

**Laboratory Tests:** Activated partial thromboplastin time (aPTT) should be monitored daily in patients with increased risk of bleeding and/or renal impairment. Serum creatinine should be monitored daily in patients with renal impairment. Peak aPTT should not exceed two times control. Should peak aPTT exceed this level, dose reduction is advised based on the degree of aPTT abnormality (see **DOSAGE and ADMINISTRATION, Initial Dosage, Use in Renal Insufficiency**). If necessary, therapy with desirudin should be interrupted until aPTT falls to less than two times control, at which time treatment with desirudin can be resumed at a reduced dose. (See **Drug Interactions** for information on use of Iprivask in conjunction with other drugs affecting coagulation). Thrombin time (TT) is not a suitable test for routine monitoring of Iprivask therapy (see **CLINICAL PHARMACOLOGY, Mechanism of Action**). Dose adjustments based on serum creatinine may be necessary (see **DOSAGE AND ADMINISTRATION, Use in Renal Insufficiency**).

**Drug Interactions:** Any agent which may enhance the risk of hemorrhage should be discontinued prior to initiation of desirudin therapy. These agents include medications such as Dextran 40, systemic glucocorticoids, thrombolytics, and anticoagulants. If co-administration cannot be avoided, close clinical and laboratory monitoring should be conducted. During prophylaxis of venous thromboembolism, concomitant treatment with heparins (unfractionated and low-molecular weight heparins) or dextrans is not recommended. The effects of desirudin and unfractionated heparins on prolongation of aPTT are additive.

As with other anticoagulants, desirudin should be used with caution in conjunction with drugs which affect platelet function. These medications include systemic salicylates, NSAIDs including ketorolac, acetylsalicylic acid, ticlopidine, dipyridamole, sulfinpyrazone, clopidogrel, abciximab and other glycoprotein IIb/IIIa antagonists (see **PRECAUTIONS, Laboratory Tests**).

*Use in patients switching from oral anticoagulants to Iprivask or from Iprivask to oral anticoagulants.* The concomitant administration of warfarin did not significantly affect the pharmacokinetic effects of desirudin. When warfarin and desirudin were co-administered, greater inhibition of hemostasis measured by activated partial thromboplastin time (aPTT), prothrombin time (PT), and international normalized ratio (INR) was observed. If a patient is switched from oral anticoagulants to Iprivask therapy or from Iprivask to oral anticoagulants, the anticoagulant activity should continue to be closely monitored with appropriate methods. That activity should be taken into account in the evaluation of the overall coagulation status of the patient during the switch.

**Animal Pharmacology and Toxicology: General Toxicity**

Desirudin produced bleeding, local inflammation, and granulation at injection sites in rat and dog toxicity studies. In a 28-day study in Rhesus monkeys, there was also evidence of subcutaneous bleeding and local inflammation at the injection sites. In addition, desirudin was immunogenic in dogs and formed antibody complexes resulting in prolonged half-life and accumulation. Desirudin showed sensitization potential in guinea pig immediate and delayed hypersensitivity models.

*Carcinogenesis, Mutagenesis, Impairment of Fertility.* No long-term studies in animals have been performed to evaluate the carcinogenic potential of desirudin.

Desirudin was not genotoxic in the Ames test, the Chinese hamster lung cell (V79/HGPRT) forward mutation test or the rat micronucleus test. It was, however, equivocal in its genotoxic effect in Chinese hamster ovarian cell (CCL 61) chromosome aberration tests.

Desirudin at subcutaneous doses up to 10mg/kg/day (about 2.7 times the recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.

**Pregnancy: Teratogenic Effects:** Pregnancy Category C. Teratology studies have been performed in rats at subcutaneous doses in a range of 1 to 15 mg/kg/day (about 0.3 to 4 times the recommended human dose based on body surface area) and in rabbits at IV doses in a range of 0.6 to 6 mg/kg/day (about 0.3 to 3 times the recommended human dose based on body surface area) and have revealed desirudin to be teratogenic. Observed teratogenic findings were: omphalocele, asymmetric and fused sternebrae, edema, shortened hind limbs, etc. in rats; and spina bifida, malrotated hind limb, hydrocephaly, gastroschisis, etc. in rabbits. There are no adequate and well controlled studies in pregnant women. Iprivask should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Nursing Mothers:** It is not known whether desirudin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when desirudin is administered to a nursing woman.

**Pediatric Use:** Safety and effectiveness in pediatric patients have not been established.



**Geriatric Use:** In three clinical studies of Iprivask, the percentage of patients greater than 65 years of age treated with 15 mg of Iprivask subcutaneously every 12 hours was 58.5%, while 20.8% were 75 years of age or older. Elderly patients treated with Iprivask had a reduction in the incidence of VTE similar to that observed in the younger patients, and a slightly lower incidence of VTE compared to those patients treated with heparin or enoxaparin.

Regarding safety, in the clinical studies the incidence of hemorrhage (major or otherwise) in patients 65 years of age or older was similar to that in patients less than 65 years of age. In addition, the elderly had a similar incidence of total, treatment-related, or serious adverse events compared to those patients less than 65 years of age. Serious adverse events occurred more frequently in patients 75 years of age or older as compared to those less than 65 years of age. In general, 15 mg desirudin every 12 hours can be used safely in the geriatric population as in the population of patients less than 65 years of age so long as renal function is adequate (see **CLINICAL PHARMACOLOGY, Special Populations, Renal Insufficiency, DOSAGE and ADMINISTRATION, Use in Renal Insufficiency**).

## ADVERSE REACTIONS

In the Phase II and III clinical studies, desirudin was administered to 2159 patients undergoing elective hip replacement surgery to determine the safety and efficacy of Iprivask in preventing VTE in this population. Below is the safety profile of the Iprivask 15 mg (q12h) regimen from these 5 multicenter clinical trials.

**Hemorrhagic Events:** The following rates of hemorrhagic events have been reported during clinical trials.

**Hemorrhage in Patients Undergoing Hip Replacement Surgery**

	Dosing Regimen		
	<b>Iprivask</b> 15 mg q12h SC N=1561 n (%)	<b>Heparin</b> 5000 IU q8h SC N=501 n (%)	<b>Enoxaparin</b> 40 mg QD SC N=1036 n (%)
Patients with Any Hemorrhage <sup>a</sup>	464 (30)	111 (22)	341 (33)
Patients with Serious Hemorrhage <sup>b</sup>	41 (3)	15 (3)	21 (2)
Patients with Major Hemorrhage <sup>c</sup>	13 (<1)	0 (0)	2 (<1)

<sup>a</sup> Includes hematomas which occurred at an incidence of 6% in the Iprivask and enoxaparin treatment groups and 5% in the heparin treatment group.

<sup>b</sup> Bleeding complications were considered *serious* if perioperative transfusion requirements exceeded 5 units of whole blood or packed red cells, or if total transfusion requirements up to postoperative Day 6 inclusive exceeded 7 units of whole blood or packed red cells, or total blood loss up to postoperative Day 6 inclusive exceeded 3500 mL.

<sup>c</sup> Bleeding complications were considered *major* if the hemorrhage was: (1) overt and it produced a fall in hemoglobin of  $\geq 2$ g/dL or if it lead to a transfusion of 2 or more units of whole or packed cells outside the perioperative period (the time from start of surgery until up to 12 hours after); (2) Retroperitoneal, intracranial, intraocular, intraspinal, or occurred in a major prosthetic joint

**Non-hemorrhagic Events:** Non-hemorrhagic adverse events occurring at  $\geq 2\%$  incidence in patients treated with Iprivask 15 mg (q 12h) during elective hip replacement surgery *and* considered to be remotely, possibly, or probably related to desirudin are provided below.

**Adverse Events Occurring at  $\geq 2\%$  in Iprivask Treated Patients  
Undergoing Hip Replacement Surgery<sup>a,b</sup>**

	<u>Iprivask</u> 15 mg q12h SC N=1561 n (%)	<u>Heparin</u> 5000 IU q8h SC N=501 n (%)	<u>Enoxaparin</u> 40 mg QD SC N=1036 n (%)
<b>Body System</b> (Preferred Term)			
Injection Site Mass	56 (4)	32 (6)	7 (<1)
Wound Secretion	59 (4)	23 (5)	34 (3)
Anemia	51 (3)	11 (2)	37 (4)
Deep Thrombophlebitis	24 (2)	41 (8)	22 (2)
Nausea	24 (2)	5 (<1)	10 (<1)

<sup>a</sup> Represents events reported while on treatment, excluding unrelated adverse events

<sup>b</sup> All hemorrhages that occurred are included in **ADVERSE REACTIONS, Hemorrhagic Events**.

*Related Adverse Events with a Frequency of <2% and >0.2%* (in decreasing order of frequency): thrombosis, hypotension, leg edema, fever, decreased hemoglobin, hematuria, dizziness, epistaxis, vomiting, impaired healing, cerebrovascular disorder, leg pain, hematemesis.

*Allergic Reactions.* In clinical studies, allergic events were reported <2% overall and in 2% of patients who were administered 15 mg desirudin. (See **PRECAUTIONS, General, Antibodies/ Re-exposure**).

**Post Marketing:** In addition to adverse events reported from clinical trials the following adverse events have been identified during post approval use of Iprivask. These events were reported voluntarily from a population of unknown size and the frequency of occurrence cannot be determined precisely: rare reports of major hemorrhages, some of which were fatal, and anaphylactic/anaphylactoid reactions.

## OVERDOSAGE

In case of overdose, most likely reflected in hemorrhagic complications or suggested by excessively high aPTT values, Iprivask therapy should be discontinued. Emergency procedures should be instituted as appropriate (for example, determination of aPTT and other coagulation levels, hemoglobin, the use of blood transfusion or plasma expanders).

No specific antidote for Iprivask is available; however, the anticoagulant effect of desirudin is partially reversible using thrombin-rich plasma concentrates while aPTT levels can be reduced by the IV administration of 0.3  $\mu\text{g}/\text{kg}$  DDAVP (desmopressin). The clinical effectiveness of DDAVP in treating bleeding due to desirudin overdose has not been studied. In an open, pilot, dose-ascending study to assess safety, the highest dose of desirudin (40 mg q12h) caused excessive hemorrhage.

## DOSAGE AND ADMINISTRATION

All patients should be evaluated for bleeding disorder risk before prophylactic administration of Iprivask (see **PRECAUTIONS, Drug Interactions**).

**Initial Dosage:** In patients undergoing hip replacement surgery, the recommended dose of Iprivask is **15 mg every 12 hours** administered by subcutaneous injection with the initial dose given up to 5 to 15 minutes prior to surgery, but *after* induction of regional block anesthesia, if used (see

**WARNINGS, Spinal/Epidural Anesthesia).** Up to 12 days administration (average duration 9 to 12 days) of Iprivask has been well tolerated in controlled clinical trials.

*Use in Renal Insufficiency*

Degree of Renal Insufficiency	Creatinine Clearance [mL/min/1.73 m <sup>2</sup> body surface area]	aPTT Monitoring & Dosing Instructions
Moderate	≥31 to 60	Initiate therapy at 5 mg every 12 hours by subcutaneous injection. Monitor aPTT and serum creatinine at least daily. <i>If</i> aPTT exceeds 2 times control: 1. Interrupt therapy until the value returns to less than two times control 2. Resume therapy at a reduced dose guided by the initial degree of aPTT abnormality
Severe <sup>a</sup>	<31	Initiate therapy at 1.7 mg every 12 hours. Monitor aPTT and serum creatinine at least daily. <i>If</i> aPTT exceeds 2 times control: 1. Interrupt therapy until the value returns to less than 2 times control 2. Consider further dose reductions guided by the initial degree of aPTT abnormality

<sup>a</sup> See **CLINICAL PHARMACOLOGY, Special Populations, Renal Insufficiency** and **WARNINGS, Renal Insufficiency**.

*Use in Hepatic Insufficiency.* In the absence of clinical studies in this population, dosing recommendations cannot be made at this time (see **CLINICAL PHARMACOLOGY, Metabolism, Special Populations, Hepatic Insufficiency**, and **PRECAUTIONS, Hepatic Insufficiency**).

**Administration: Directions on Preparation**

Use Iprivask before the expiration date given on the carton and container.

1. Reconstitution should be carried out under sterile conditions.
2. Reconstitute each vial with 0.5 mL of provided diluent [Mannitol USP (3%) in Water for Injection]. Once reconstituted, each 0.5 mL contains 15.75 mg of desirudin.
3. Shake the vial gently until the drug is fully reconstituted.
4. Reconstituted Iprivask is a clear colorless solution. Inspect Iprivask visually for particulate matter and discoloration prior to administration. Do not use solutions that are cloudy or contain particles.
5. Use a syringe with a 26 or 27 gauge needle which is approximately ½ inch in length to withdraw all of the reconstituted solution (15.75 mg desirudin/0.5 mL) and inject the entire contents of the syringe subcutaneously which will deliver 15 mg.
6. The reconstituted solution should be used immediately; however, it is stable for up to 24 hours when stored at room temperature and protected from light. Discard any unused solution appropriately.

Iprivask should not be mixed with other injections, solvents, or infusions. Iprivask is administered by subcutaneous injection. It must not be administered by intramuscular injection.

*Subcutaneous Injection Technique:* Select a syringe with a 26 or 27 gauge needle which is approximately ½ inch in length for administration of Iprivask. Withdraw the entire reconstituted solution (15.75 mg desirudin/0.5 mL) into the syringe and inject the total volume subcutaneously.

Patients should be sitting or lying down and Iprivask injection administered by deep subcutaneous injection. Administration should be alternated between the left and right anterolateral and left and right posterolateral thigh or abdominal wall. The whole length of the needle should be introduced into a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection. To minimize bruising, do not rub the injection site after completion of the injection.

## HOW SUPPLIED

Iprivask [Desirudin for Injection] is supplied as a single dose (15.75 mg) lyophilized powder with an accompanying sterile, non-pyrogenic diluent [0.6 mL of Mannitol USP (3%) in Water for Injection]. It is available in the following presentations:

- Two vials each containing 15.75 mg of desirudin with two ampules of 0.6 mL Mannitol (3%) in Water for Injection, NDC 0075-2300-02
- Ten vials each containing 15.75 mg of desirudin with ten ampules of 0.6 mL Mannitol (3%) in Water for Injection, NDC 0075-2300-10.

**Storage:** Protect from light.

*Unopened vials or ampules:* Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). [See USP Controlled Room Temperature.]

**Keep this and all medicines out of the reach of children.**

Distributed by:

**AVENTIS Pharmaceuticals Inc.**

Bridgewater, NJ 08807

Made in Germany

Rev \_\_\_/\_\_\_

Text for Iprivask vial label

NDC 0075-2300-01

Iprivask™ 15 mg

(Desirudin for Injection)

Contains 15.75 mg to deliver 15 mg

FOR SUBCUTANEOUS INJECTION

**Rx only**

**Directions for use:** see insert. Each Iprivask Vial contains 15.75 mg desirudin and the following inactive ingredients: 1.31 mg anhydrous magnesium chloride USP, sodium hydroxide for injection USP.

Dist by: **Aventis****Pharmaceuticals Inc.**

Bridgewater, NJ 08807

Made in Germany

Text for Diluent ampule label

NDC XXXX-XXX-XX

Mannitol Injection 3%

For use as a Diluent 0.6 mL

Contents:

Mannitol USP (3% w/v)

in Water for Injection USP.

**Rx only**

**Directions for use:** see insert.

Dist by: **Aventis****Pharmaceuticals Inc.**

Bridgewater, NJ 08807

Made in Germany

Text for Iprivask carton labels (Text for cartons of 10 are identical to text for cartons of 2)

Top flap

Iprivask™ 15 mg  
(Desirudin for Injection)

Two (2) x 15.75 mg Single Dose Vials  
Two (2) x 0.6 mL Ampules of Diluent

Front panel

NDC 0075-2300-02

Iprivask™ 15 mg  
(Desirudin for Injection)

Contents:

Two (2) x 15 15.75 mg Single Dose Vials  
Two (2) x 0.6 mL Ampules of Diluent  
FOR SUBCUTANEOUS INJECTION

(logo) Aventis

Back panel

**Rx only**

Each **vial** contains 15.75 mg desirudin (as a lyophilized powder which requires reconstitution) and the following inactive ingredients: 1.31 mg anhydrous magnesium chloride USP, sodium hydroxide for Injection USP.

Single dose vials. Discard unused portion.

Each **ampule** contains 0.6 mL Mannitol USP (3% w/v) in Water for Injection provided as a diluent for the desirudin lyophilized powder.

Usual Dosage: See package insert.

Directions for Reconstitution: Reconstitute under sterile conditions. Inject 0.5 mL Mannitol Injection 3% into IPRIVASK vial. Shake vial gently until drug is fully reconstituted. Inspect solution for particulate matter and discoloration prior to administration. Each 0.5 mL of the reconstituted solution contains 15.75 mg desirudin to deliver 15 mg.

Protect from light.

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room temperature.]

Once IPRIVASK is reconstituted it may be used for up to 24 hours, when stored as indicated above. After 24 hours discard the solution.

Distributed by:  
Aventis Pharmaceuticals Inc.  
Bridgewater, NJ 08807  
Made in Germany

Side panels

NDC 0075-2300-02  
Iprivask™ 15 mg  
(Desirudin for Injection)

Contents:  
Two (2) x 15 15.75 mg Single Dose Vials  
Two (2) x 0.6 mL Ampules of Diluent  
FOR SUBCUTANEOUS INJECTION

(logo) Aventis